Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial
- Supplementary File 1:
PDF-Document (PDF, 375 KiB)
Brownstein, M.J.; Simon, N.G.; Long, J.D.; Yankey, J.; Maibach, H.T.; Cudkowicz, M.; Coffey, C.; Conwit, R.A.; Lungu, C.; Anderson, K.E.; Hersch, S.M.; Ecklund, D.J.; Damiano, E.M.; Itzkowitz, D.E.; Lu, S.; Chase, M.K.; Shefner, J.M.; McGarry, A.; Thornell, B.; Gladden, C.; Costigan, M.; O'Suilleabhain, P.; Marshall, F.J.; Chesire, A.M.; Deritis, P.; Adams, J.L.; Hedera, P.; Lowen, K.; Rosas, H.D.; Hiller, A.L.; Quinn, J.; Keith, K.; Duker, A.P.; Gruenwald, C.; Molloy, A.; Jacob, C.; Factor, S.; Sperin, E.; Bega, D.; Brown, Z.R.; Seeberger, L.C.; Sung, V.W.; Benge, M.; Kostyk, S.K.; Daley, A.M.; Perlman, S.; Suski, V.; Conlon, P.; Barrett, M.J.; Lowenhaupt, S.; Quigg, M.; Perlmutter, J.S.; Wright, B.A.; Most, E.; Schwartz, G.J.; Lamb, J.; Chuang, R.S.; Singer, C.; Marder, K.; Moran, J.A.; Singleton, J.R.; Zorn, M.; Wall, P.V.; Dubinsky, R.M.; Gray, C.; Drazinic, C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial. J. Clin. Med. 2020, 9, 3682.
Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine. 2020; 9(11):3682.
Chicago/Turabian StyleBrownstein, Michael J.; Simon, Neal G.; Long, Jeffrey D.; Yankey, Jon; Maibach, Hilda T.; Cudkowicz, Merit; Coffey, Christopher; Conwit, Robin A.; Lungu, Codrin; Anderson, Karen E.; Hersch, Steven M.; Ecklund, Dixie J.; Damiano, Eve M.; Itzkowitz, Debra E.; Lu, Shifang; Chase, Marianne K.; Shefner, Jeremy M.; McGarry, Andrew; Thornell, Brenda; Gladden, Catherine; Costigan, Michele; O'Suilleabhain, Padraig; Marshall, Frederick J.; Chesire, Amy M.; Deritis, Paul; Adams, Jamie L.; Hedera, Peter; Lowen, Kelly; Rosas, H. D.; Hiller, Amie L.; Quinn, Joseph; Keith, Kellie; Duker, Andrew P.; Gruenwald, Christina; Molloy, Angela; Jacob, Cara; Factor, Stewart; Sperin, Elaine; Bega, Danny; Brown, Zsazsa R.; Seeberger, Lauren C.; Sung, Victor W.; Benge, Melanie; Kostyk, Sandra K.; Daley, Allison M.; Perlman, Susan; Suski, Valerie; Conlon, Patricia; Barrett, Matthew J.; Lowenhaupt, Stephanie; Quigg, Mark; Perlmutter, Joel S.; Wright, Brenton A.; Most, Elaine; Schwartz, Guy J.; Lamb, Jessica; Chuang, Rosalind S.; Singer, Carlos; Marder, Karen; Moran, Joyce A.; Singleton, John R.; Zorn, Meghan; Wall, Paola V.; Dubinsky, Richard M.; Gray, Carolyn; Drazinic, Carolyn. 2020. "Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial" J. Clin. Med. 9, no. 11: 3682.